Bausch Health to Reaffirm High-End 2025 Guidance at J.P. Morgan Conference
BHC sits 76% above its 52-week low of $4.25.
Summary
Bausch Health announced it expects to reaffirm its full-year 2025 guidance at the higher end of the range for its core business, excluding Bausch + Lomb, during its presentation at the J.P. Morgan Healthcare Conference.
Key Events · Earnings and Guidance · BHC
-
Guidance Reaffirmation
Bausch Health expects to reaffirm its full-year 2025 guidance at the higher end of the previously provided range, specifically for Bausch Health excluding Bausch + Lomb Corporation.
-
J.P. Morgan Healthcare Conference
The company will provide strategic and business updates during its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Analysis · BHC · Life Sciences
Bausch Health's announcement to reaffirm its full-year 2025 guidance at the higher end of the range, specifically for Bausch Health excluding Bausch + Lomb Corporation, signals management's confidence in its operational performance. This update, provided ahead of a major industry conference, suggests a positive outlook and could reassure investors regarding the company's financial trajectory for the core business.
At the time of this filing, BHC was trading at $7.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $4.25 to $8.69. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.